456例新型冠状病毒肺炎患者抗病毒药物应用分析  

Applications of antiviral drugs in 456 patients with COVID-19

作　　者：杨帆[1] 马海平 尤萌茹 廖沙 刘兰 朱军 YANG Fan;MA Haiping;YOU Mengru;LIAO Sha;LIU Lan;ZHU Jun(Department of Pharmacy,Xiantao First People’s Hospital Affiliated to Yangtze University,Xiantao Hubei 433000,China;Department of Pharmacy,Dongfeng Hospital Affiliated to Hubei Medical University,Shiyan Hubei 442000,China)

机构地区：[1]长江大学附属仙桃市第一人民医院药学部,湖北仙桃433000 [2]湖北医药学院附属东风医院药学部,湖北十堰442000

出　　处：《中国药物警戒》2022年第4期413-416,共4页Chinese Journal of Pharmacovigilance

摘　　要：目的对新型冠状病毒肺炎(COVID-19)患者的临床特点及抗病毒药物应用现状进行分析,为临床合理用药提供参考。方法收集2020年2月1日至29日仙桃市第一人民医院456例COVID-19患者的病例资料,对患者特征、抗病毒药物用法用量、联合使用情况及药品不良反应(ADR)进行回顾性分析。结果456例COVID-19患者中,30~65岁患者占71.71%,抗病毒药物用法用量基本符合国家诊疗方案,单药治疗为主,联用用药比例为8.78%,阿比多尔使用频率最高,29例患者发生了ADR,主要表现为恶心、呕吐、纳差。结论我院COVID-19患者抗病毒药物使用基本合理,少数患者抗病毒药物品种达3种以上,应重视其合理性和安全性。Objective To evaluate the clinical characteristics of COVID-19 patients and current usage of antiviral drugs in our hospital to provide data for rational use drugs in cliuic.Methods The clinical data on COVID-19 patients diagnosed in Xiantao First People’s Hospital from February 1 to February 29,2020,their characteristics,as well as the usage,dosage and combined use of antiviral drugs and adverse drug reactions(ADR)were analyzed retrospectively.Results A total of 456 patients were collected.Patients aged 30 to 65 accounted for 71.71%.The usage and dosage of antiviral drugs basically conformed to the national diagnosis and treatment plans.Monotherapy was the main treatment,combined use of antiviral drugs accounted for 8.78%,and arbidol was the most frequently used.ADR occurred in 29 patients,and the main symptoms were nausea,vomiting and poor appetite.Conclusion The use of antiviral drugs in patients with COVID-19 was generally appropriate,but a few patients were treated with three or more types of antiviral drugs.

关 键 词：新型冠状病毒肺炎 抗病毒药物 回顾性研究 药品不良反应 

分 类 号：R978.7[医药卫生—药品]